| Submit your comments on this article |
| Science & Technology |
| Covid-19 vaccine in Brazil |
| 2020-09-10 |
| Russia's sovereign wealth fund RDIF said on Thursday that it had agreed to manufacture Russia's first registered COVID-19 vaccine "Sputnik-V" in Brazil. RDIF, which is backing the vaccine's development, also said it planned to supply up to 100 million doses of the vaccine to Latin America. |
| Posted by:g(r)omgoru |
| #6 US: we got da bill o rights, free speech, we'd never destroy people for incorrect speech - not us no siree, no never... Russia: say whatever you like, no "RayCiss!!!" no cancel culture - so long as you don't threaten the oligarchs incl Putin... US: oligarchs? What, us oligarchs?? No oligarchs to see here, move along now... [Your winnings Sir. Thank you.] Russia: yes there are oligarchs. Bandits. Assholes who lie cheat steal. Are you telling us that Bezos Fuckerberg GooGooBlyz didn't pay off your politicians and bend the competition rules and the "platform, not publisher" scam in their favor? Are you retarded? |
| Posted by: Elmusoger Pheatch6429 2020-09-10 21:09 |
| #5 And we are supposed to summarily trust Big Pharma outside of Russia? Hardly. I sense mucho jealousy (from Big Pharma, Wall Street, FDA) because the Russians appears for the moment to have won the vaccine race. Of course, time will tell. |
| Posted by: Clem 2020-09-10 20:32 |
| #4 Brazil trials of Sinovac COVID-19 vaccine show promising results - governor |
| Posted by: Skidmark 2020-09-10 15:32 |
| #3 Me: I wonder if the WuFlu coverage is making people hysterical? Brazil: Yeah sure we volunteer to be injected by an untested Russian vaccine sold with sketchy data. |
| Posted by: swksvolFF 2020-09-10 15:19 |
| #2 This is the vaccine that is barely in Phase 1 trials with hinky data? In an open letter to the editor of The Lancet medical journal, in which Russia’s Gamaleya Research Institute of Epidemiology and Microbiology published early-stage trial results of its coronavirus vaccine last Friday, a group of scientists said the data was incomplete and had shown some “unlikely patterns.” They said the results showed that groups of participants had reported identical antibody levels at different points in the study. There are 27 signatories of the letter so far — predominantly scientists based in Europe but also including several in the U.S. and Asia. “There are several data patterns which appear repeatedly for the reported experiments,” the open letter said. “On the ground of simple probabilistic evaluations the fact of observing so many data points preserved among different experiments is highly unlikely.” The scientists were also concerned at the lack of original numerical data presented in The Lancet, saying that “no conclusions can be definitively drawn on the reliability of the data presented, especially regarding the apparent duplications detected.” Good Luck. They will need it. |
| Posted by: Sholutle Uleling6061 2020-09-10 14:20 |
| #1 Large scale human trial. I wish them well. |
| Posted by: Iblis 2020-09-10 12:43 |